Proof-of-concept trials with anti-interleukin (IL)5 (reslizumab, mepolizumab), anti-IgE (omalizumab), and anti-IL4 receptor alpha (dupilumab) in chronic rhinosinusitis with nasal polyps (CRSwNPs) recently revealed an innovative therapeutic potential.1 Here, IGHE is linked to Nasal polyposis.